TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical (OTCQB: TOMDF) has paused enrollment in its Phase 2 clinical trial of Tollovir®, an antiviral candidate for COVID-19, to conduct an interim analysis. The analysis will now involve 31 patients instead of the planned 33, as recommended by the statistician due to indications of futility. Results are expected by the end of Q4 2021. The trial aims to assess hospitalization duration and clinical improvement metrics. Jules Mitchel, PhD, has been appointed as a strategic advisor for the interim analysis, leveraging his extensive clinical research experience.

Todos Medical, Ltd. (OTCQB: TOMDF) has signed an exclusive European licensing agreement with T-Cell Protect Hellas S.A. for the distribution of its Tollovid® dietary supplements across 30 countries, targeting a minimum of 500,000 bottles in sales over 18 months. T-Cell Protect will invest 1 million euros in Todos to advance the development of Tollovir, an antiviral treatment candidate. The agreement is expected to generate revenue starting in the current quarter, showcasing Todos' strategic partnership in the growing immune support market.

Todos Medical, Ltd. (OTCQB: TOMDF) announced the reauthorization of Emergency Use Authorization (EUA) for its cPass neutralizing antibody test. The reauthorization now includes both qualitative and semi-quantitative detection of total neutralizing antibodies to SARS-CoV-2 in human serum and plasma. This test is crucial for identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior or recent infection. CEO Gerald Commissiong will discuss this development on Cheddar News at 6:10 PM tonight, November 17th, 2021.

Todos Medical (OTCQB: TOMDF) announced its Q3 2021 financial results, reporting revenues of $1.01 million, down from $1.28 million in Q3 2020. The decrease is attributed to a shift from equipment to reagent sales in its COVID-19 diagnostics business. Operating loss decreased to $(2.5 million) from $(10.2 million) year-over-year. The company integrated COVID-19 PCR automation at its Provista lab, expected to boost testing capacity significantly. Tollovid and Tollovid Daily received authorization for sale on Amazon and Alibaba, enhancing market presence. Interim results for the Tollovir clinical trial are anticipated soon.

Todos Medical (OTCQB: TOMDF) announced a reference lab agreement with a CLIA laboratory in Atlanta. Through its subsidiary Provista Diagnostics, the company will provide COVID PCR, cPass Neutralizing Antibody, and Respiratory Pathogen Panel testing, aiming for under 12-hour turnaround times. Initially, 2,000 COVID PCR tests monthly are anticipated, with potential for growth. The demand for rapid testing is high due to a projected harsh cold and flu season. CEO Gerald E. Commissiong highlighted the momentum in business development and the potential for significant revenue growth from this agreement.

Todos Medical, Ltd. (OTCQB: TOMDF) reported Q3 2021 financial results with total revenue of $1.01 million, down from $1.28 million in Q3 2020, driven by a shift to reagent sales. The company recorded a reduced operating loss of $(2.5 million) compared to $(10.2 million) in Q3 2020. A notable highlight includes positive clinical data for Tollovir, with no deaths in the treated group. The company also expects increased revenue from its newly automated Provista lab and anticipates a surge in COVID testing this winter.

Todos Medical (OTCQB: TOMDF) reports a surge in PCR testing at its Provista Diagnostics lab, conducting over 7,600 tests in October alone, surpassing the total from the first eight months of 2021. With new automation, testing capacity is set to increase to 20,000 tests per day. The company anticipates significant revenue growth from COVID PCR and antibody testing in upcoming quarters. President & CEO Gerald Commissiong emphasizes the company's strategy to expand marketing and testing offerings. Todos is also presenting at the GCFF Virtual Conference on November 4, 2021.

Todos Medical, Ltd. (OTCQB: TOMDF) adds Hillel Yaffe Medical Center in Israel as the second site for its Phase 2 clinical trial of Tollovir, an antiviral candidate for hospitalized COVID-19 patients. The initial site, Shaare Zedek Medical Center, has enrolled 30 patients. An independent review of interim data is expected in Q4 2021 to inform further development. The recent publications in Nature Neuroscience and Cell Reports support the therapeutic's efficacy, prompting evaluations for use beyond hospitalized patients, potentially including moderate COVID cases and pediatric applications.

Todos Medical, Ltd. (OTCQB: TOMDF) announced CEO Gerald Commissiong's upcoming presentation at the Benzinga Global Small Cap Conference on October 28, 2021, at 1:55 PM ET. The company is focused on its Phase 2 clinical trial for Tollovir®, aiming to treat hospitalized COVID-19 patients. Key publication highlights Mpro's role in brain-related COVID-19 symptoms. Todos continues to innovate in diagnostics for cancer and neurodegenerative disorders from its base in Israel and New York.